For optimal management and to minimize immunotherapy-associated hepatitis, it is critical to evaluate liver function parameters (GOT, GPT, GGT, AP, bilirubin) and hepatic synthesis parameters (albumin, INR) by laboratory testing prior to initiating immune checkpoint inhibitor therapy and to rule out pre-existing liver disease and viral hepatitis. This evidence concerns the gene ALB and Hepatitis.